| 54.58 -1.63 (-2.9%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 69.82 | 1-year : | 75.91 |
| Resists | First : | 59.78 | Second : | 65 |
| Pivot price | 59.44 |
|||
| Supports | First : | 51.34 | Second : | 42.71 |
| MAs | MA(5) : | 57.17 |
MA(20) : | 58.55 |
| MA(100) : | 49.65  |
MA(250) : | 41.73 |
|
| MACD | MACD : | 0.7 |
Signal : | 1.6 |
| %K %D | K(14,3) : | 16 |
D(3) : | 28 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 76.61 | Low : | 27.65 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PCVX ] has closed below the lower bollinger band by 6.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ PCVX ] is to continue within current trading range. Bollinger Bands are 11.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 57.99 - 58.39 | 58.39 - 58.7 |
| Low: | 52.24 - 52.76 | 52.76 - 53.16 |
| Close: | 53.85 - 54.56 | 54.56 - 55.11 |
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Sat, 14 Mar 2026
Pivotal bioVenture Partners Investment Advisor LLC Raises Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Fri, 13 Mar 2026
Vaxcyte, Inc. $PCVX Holdings Lowered by Capital Research Global Investors - MarketBeat
Thu, 12 Mar 2026
Victory Capital Management Inc. Lowers Stock Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Wed, 11 Mar 2026
Vaxcyte (PCVX) finance SVP exercises options and sells 2,500 shares - Stock Titan
Wed, 11 Mar 2026
Vaxcyte (PCVX) COO logs planned stock sales and RSU tax withholding - Stock Titan
Tue, 10 Mar 2026
Jefferies Maintains Buy on Vaxcyte (PCVX) March 10, 2026 - Meyka
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 144 (M) |
| Shares Float | 132 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 104.3 (%) |
| Shares Short | 13,760 (K) |
| Shares Short P.Month | 12,100 (K) |
| EPS | -5.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 20.48 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.8 % |
| Return on Equity (ttm) | -25.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -656 (M) |
| Levered Free Cash Flow | -431 (M) |
| PE Ratio | -9.7 |
| PEG Ratio | 0 |
| Price to Book value | 2.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|